- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Otsuka Phama. Co., Ltd. v. Zydus Pharms. USA, Inc., et al.
Allowing certification for appeal of patent with severable invention from remaining patents in suit.
July 21, 2016
![GENERICally Speaking: A Hatch Waxman Litigation Bulletin](/-/media/images/newsletters/generically-speaking-social-graphics/generically-speaking-nwsltr-badge.jpg?la=en&h=160&w=390&la=en&hash=314B8432ED62E0647D7FC4565EC18B79)
Case Name: Otsuka Phama. Co., Ltd. v. Zydus Pharms. USA, Inc., et al., Civil Action Nos. 14-3168 (JBS/KMW), 2016 U.S. Dist. LEXIS 48689 (D.N.J. Apr. 12, 2016) (Simandle, C.J.)
Drug Product and Patent(s)-in-Suit: Abilify® (aripiprazole); U.S. Patents Nos. 5,006,528 (“the ’528 patent”), 7,053,092 (“the ’092 patent”), 8,017,615 (“the ’615 patent”), 8,580,796 (“the ’796 patent”), 8,462,600 (“the ’600 patent”), 8,642,760 (“the ’760 patent”), and 8,739,350 (“the ’350 patent”)
Nature of the Case and Issue(s) Presented: The court construed the claims of the asserted patents, including the ’350 patent. The ’350 patent used the terms “a/the pharmaceutical composition” and “in combination with,” which the court construed as “a single dosage form, or ‘pharmaceutical composition’ containing at least two active ingredients: aripiprazole and at least one of citalopram, escitalopram and salt thereof.” In light of the construction, the parties stipulated to non-infringement of the ’350 patent. Otsuka sought certification of the stipulated judgments under Fed. R. Civ. P. 54(b) on the grounds that the now-resolved ’350 patent infringement claims presented issues severable from and not intertwined with the remaining infringement claims and counterclaims raised in related actions. The court granted certification.
Why Otsuka Prevailed: Certification for appeal requires: (i) a final judgment on the merits; and (ii) no just reason for delay. Here, there was no dispute that a final judgment existed—the parties stipulated to non-infringement such that no litigable issues remained regarding the ’350 patent. Although the court was initially skeptical due to Otsuka’s delay in seeking certification, it found that no reason for delay. The specification of the ’350 patent was different from the specifications of the other asserted patents, and the claims related to a method of use, not a specific polymorphic formulation. Thus, the ’350 patent implicated an analysis different from that of the other patents-in-suit. Accordingly, the Court permitted certification of the ’350 patent infringement claims.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.